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Abstract: Cardiovascular disease remains a major cause of morbidity and mortality in the 
westernized world. Atherosclerosis is the underlying cause of most cardiovascular diseases. 
Atherosclerosis is a slowly evolving chronic inflammatory disorder involving the intima 
of large and medium sized arteries that is initiated in response to high plasma lipid levels, 
especially LDL. Cells of both the innate and adaptive immunity are involved in this chronic 
inflammation. Although high plasma LDL levels are a major contributor to most stages of the 
evolution of atherosclerosis, HDL and its major protein apoA-I possess properties that attenuate 
and may even reverse atherosclerosis. Two major functions are the ability to induce the efflux 
of cholesterol from cells, particularly lipid-loaded macrophages, in the artery wall for transfer 
to the liver, a process referred to as reverse cholesterol transport, and the ability to attenuate 
the pro-inflammatory properties of LDL. The removal of cellular cholesterol from lipid-loaded 
macrophages may also be anti-inflammatory. One of the most promising therapies to enhance the 
anti-atherogenic, anti-inflammatory properties of HDL is apoA-I mimetic peptides. Several of 
these peptides have been shown to promote cellular cholesterol efflux, attenuate the production 
of pro-inflammatory cytokines by macrophages, and to attenuate the pro-inflammatory properties 
of LDL. This latter effect may be related to their high affinity for oxidized lipids present in LDL. 
This review discusses the functional properties of the peptides and their effect on experimental 
atherosclerosis and the results of initial clinical studies in humans.
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Introduction
Cardiovascular disease remains a major cause of morbidity and mortality in the 
  westernized world, despite the successes in reducing the outcomes of this disease con-
sequent on the aggressive use of statins, which aim to lower plasma LDL-cholesterol. 
Atherosclerosis is at the core of the largest proportion of subjects with these diseases. 
Atherosclerosis is a slowly evolving chronic inflammation involving the intima of 
large and medium-sized arteries initiated in response to high plasma lipids, especially 
LDL, and the uptake of modified LDL by macrophages in the artery wall. Components 
of both the innate and adaptive immune systems are involved.1–3 Clinically significant 
atherosclerosis manifests in mid-to-late decades of life, but it is initiated earlier with 
detectable atherosclerotic lesions present in the second to fourth decades of life.4 The 
affected arteries are the carotids, coronaries, aortic arch, renals, and femorals, resulting 
in stroke, myocardial infarction, renal stenosis, impaired function, and intermittent 
claudication, respectively. The major risk factors giving rise to atherosclerosis are 
elevated blood cholesterol (mainly LDL-cholesterol), hypertension, smoking, obesity, Journal of Inflammation Research 2011:4 submit your manuscript | www.dovepress.com
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diabetes, low HDL cholesterol, and of course age because of 
the slow evolution of vascular inflammation.5 Atherosclerotic 
lesions do not appear uniformly around the circumference of 
blood vessels. When examined in cross-section, the lesions 
are usually found on one side of the vessel lumen with the 
other side relatively lesion-free. This distribution is related 
to the hemodynamics of blood flow.6 The blood components 
most important for the initiation of atherosclerosis are lipo-
protein particles, particularly LDL, and leukocytes, mainly 
monocytes.2 In regions of laminar flow, these components 
are in the center of the blood flow in the artery, whereas in 
low shear stress areas such as at bends and branch points of 
vessels, these components spend more time in close approxi-
mation to the endothelium of the artery wall, the so-called 
near wall phenomena.6 Shear stress differences also alter 
the gene expression pattern of the endothelial cells includ-
ing changes that promote the influx of leukocytes into the 
luminal layer of the vessel wall.6 Although several arterial 
sites are susceptible to the development of atherosclerosis, 
the lesions do not develop simultaneously in all sites nor do 
all individuals develop lesions at all sites. We believe this 
to be due to subtle differences in the arterial configuration 
and hence hemodynamic influences which might imprint the 
underlying endothelial phenotype and affect the response to 
risk factors.7
LDL dysregulation  
and atherogenesis
Two genetic diseases have been most informative about the 
role of LDL in human atherosclerosis. First was the   finding 
that humans with familial hypercholesterolemia (FH), 
especially those with homozygous mutations affecting the 
function of the LDL receptor, are at significantly increased 
risk of developing premature atherosclerosis and its clinical 
sequelae.8 In the absence of normal LDL receptor function 
in the liver, plasma and LDL cholesterol are elevated several 
fold. Brown and Goldstein’s interest in understanding the 
mechanisms responsible for the phenotype in FH patients 
led them to examine the role of the LDL receptor in the 
loading of macrophages with cholesteryl ester, an impor-
tant initial step in atherogenesis. Their studies provided 
strong evidence for the relatively minor role of the LDL 
receptor in the loading of macrophages with lipids.9 Rather 
they showed that lipid loading of macrophages involved 
the uptake of modified LDL, not native LDL, by a process 
involving cell surface scavenger receptors. This observation 
accounted for the increased atherosclerosis in FH patients 
and generated important information for the subsequent study 
of   atherogenesis. This, however, does not belie the critical 
importance of the LDL receptor in plasma lipoprotein and 
cholesterol homeostasis and the impact of high plasma LDL 
levels on atherogenesis. In contrast to those patients with 
hypercholesterolemia, patients who have reduced levels 
of plasma LDL as a result of a loss of function of the gene 
encoding proprotein convertase subtilisin-like/kexin type 9 
(PCSK9) develop modest atherosclerosis.10 PCSK9 is respon-
sible for accelerating the turnover of the LDL receptor.11 Thus 
in the absence of fully functional PCSK9, cell surface LDL 
receptor, particularly that of the hepatocyte, is more abundant 
and has a longer half-life resulting in lower levels of plasma 
LDL-cholesterol. As a result these patients are exposed to 
low plasma LDL levels throughout their lifespan.
Almost all animal models of atherogenesis involve 
genetic or diet manipulations of plasma lipoprotein levels, 
particularly LDL.12 How does persistently elevated plasma 
LDL-cholesterol promote atherogenesis and how is this 
related to inflammation?1–3 With elevated plasma LDL there 
is an increased ingress of this lipoprotein into the intima of 
the vessel wall at atherosclerosis susceptible sites, where it is 
both retained by the matrix proteoglycans and modified either 
modestly or substantially by oxidation mediated by peroxi-
dase, lipoxygenase, or reactive oxygen species (ROS). The 
ROS generated in the presence of lipoxygenase results in the 
oxidation of phospholipids in the LDL, generating oxidized 
fatty acids. Cholesterol is also oxidized, forming ketocho-
lesterol which is cytotoxic.13 Modified LDL may be taken 
up by macrophages through macropinocytosis induced by 
minimally modified LDL binding to the pattern recognition 
receptor Toll-like receptor (TLR) 4 or by scavenger receptors 
expressed on the surface of monocytes that have differenti-
ated into macrophages.14 Cholesterol loading of macrophages 
has a substantial impact on networks of genes that are either 
up- or downregulated.15 If there is sufficient uptake of modi-
fied LDL, the lipoprotein cholesterol deposits in cytoplasmic 
droplets primarily as cholesteryl esters producing the foam 
cell which is the cardinal cell involved in the early stages of 
atherosclerosis. The uptake of modified lipoprotein or their 
interaction with cell surface receptors also results in the acti-
vation of a variety of signaling pathways in the macrophage 
leading to the production of cytokines, chemokines, growth 
factors, and ROS that influence the overlying endothelial 
cells and the smooth muscle cells in the vessel wall directly 
or by further modification of LDL which can also induce 
signaling in endothelial cells. The result of these regulatory 
phenomena is the production of chemotactic factors such as 
monocyte chemotactic protein 1 (MCP-1) which helps in the Journal of Inflammation Research 2011:4 submit your manuscript | www.dovepress.com
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recruitment of the monocytes into the intima, the production 
of adhesion molecules such as VCAM1 and ICAM1, and the 
secretion of granulocyte-macrophage colony-stimulating 
factor (GM-CSF) which promotes the local differentiation 
of monocytes to macrophages. Many of these proteins have 
an impact not only on the behavior of macrophages, but also 
the recruitment of other inflammatory cells. The growth fac-
tors promote the migration of smooth muscle cells from the 
arterial media into the intima, where they synthesize matrix 
proteins and are also responsible for the formation of the 
fibrous cap which overlies the maturing plaque. Other cells 
are recruited from the blood stream, most notable are T cells. 
This includes T helper 1 (TH1) cells which secrete pro-inflam-
matory cytokines such as interferon γ (IFNγ), and T regula-
tory (Treg) cells which secrete anti-inflammatory cytokines 
such as IL-10 and transforming growth factor β (TGFβ). 
The natural killer T cell subsets have also been implicated 
in atherogenesis. These T cell cytokines may influence gene 
expression in the macrophages of the lesions, including the 
expression of costimulatory molecules which participate in 
the activation of  the T cell subsets. Other minor components 
of the innate and adaptive immune system have also been 
implicated in the evolution of atherosclerosis.16
Oxidized lipids in the modified LDL produced by the 
lipoxygenase pathway can couple with the lysine residues of 
apoB, the major apoprotein in LDL.13 These changes create 
neo-antigens in the LDL which can activate the innate and 
adaptive immune system, generating antibodies that may be 
protective against the further evolution of atherosclerosis and 
implicating the participation of B cells in atherogenesis.17 The 
elicited immune reaction has led to studies of immunization 
approaches to the treatment of atherosclerotic disease mostly 
using apoB peptides as antigen.18,19 The results of these 
experimental studies show considerable promise.
As atherosclerosis proceeds, lipid-loaded macrophages 
may undergo apoptosis or necrosis. With cholesterol loading 
there is an increase in both cholesteryl ester and free choles-
terol with the latter eliciting the unfolded protein response 
and the activation of the apoptotic cascade.20 Apoptotic 
macrophages may be phagocytosed by surrounding phago-
cytes, a process designated as efferocytosis. When apoptotic 
cells are efficiently removed, this promotes inflammation 
resolution and lesions decrease in size; on the other hand, 
when efferocytosis is inefficient, apoptotic macrophages 
accumulate and may undergo secondary necrosis, creating 
the necrotic core of advancing atherosclerotic plaques and 
increasing vascular inflammation.21 These cores may include 
proteolytic enzymes and sufficient cholesterol to crystallize. 
The proteolytic enzymes may play a role in the disruption 
of the overlying fibrous cap of the atherosclerotic lesion 
made by smooth muscle cells which have migrated from the 
media. The lesions containing necrotic cores are less stable 
and may result in the formation of an acute atherothrombosis 
and possible embolization giving rise to the critical clinical 
complications of atherosclerotic vascular disease.
The above discussion highlights the importance of 
LDL and cholesterol in various stages of the vascular 
inflammation associated with atherosclerosis. Statin 
drugs inhibit 3-hydroxy-3-methyl-glutaryl-CoA (HMG 
CoA) reductase and efficiently upregulate the production 
of the LDL receptor, thus lowering plasma LDL levels, 
and are one of the most widely prescribed treatments for 
hypercholesterolemia. Despite the success of statin treatment 
in lowering the clinical outcomes in atherosclerotic disease, 
cardiovascular disease remains the major cause of morbidity 
and mortality in the westernized world. One of the reasons 
is probably attributable to the fact that statin treatment is 
usually initiated in mid-to-late life when atherosclerotic 
lesions are quite well advanced. The atherosclerotic plaque, 
though a chronic inflammatory reaction, is a dynamic 
entity and potentially capable of undergoing a “reversal”. 
The most dynamic cell component of the atherosclerotic 
plaque is likely the lipid-loaded foam cell.22 Statins alone 
seldom lower LDL-cholesterol in human studies to levels 
that induce substantial reversal of existing atherosclerotic 
lesions. Statins probably function mainly by limiting the 
progression of atherosclerotic lesions.
HDL as an atheroprotective agent
The continuing morbidity and mortality of cardiovascular 
disease in the face of widespread statin treatment has led to a 
focus on the HDL component of the plasma. There is a great 
deal of epidemiological and experimental animal evidence 
suggesting that HDL is protective against atherosclerosis and 
its sequelae.23,24 HDL is also thought to be the key player in 
the potential reversal of atherosclerosis.25,26 Several   subclasses 
of HDL exist in humans which are differentiated by size and 
density. As its name suggests HDL is denser than LDL, car-
rying a larger proportion of protein to lipids than LDL. The 
major apoproteins of HDL are apoA-I and apoA-II. However 
the recent proteomic analysis of human HDL indicates that 
many other proteins may be associated with this lipoprotein 
in subparticle stoichiometry.27,28 This suggests that when the 
minor proteins are taken into account, HDL exhibits a very 
large degree of microheterogeneity. However the precise func-
tion of many of these substoichiometric components of HDL Journal of Inflammation Research 2011:4 submit your manuscript | www.dovepress.com
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is unknown. Most attention has been focused on apoA-I 
since it is the major apoprotein in HDL, constituting about 
two-thirds of the total HDL protein and is probably a major 
component of each HDL particle. In humans, the mature 
protein contains 243 amino acids with the last 199 amino 
acids of the protein composed of a series of ten repeating 
amphipathic α-helices.29 Eight of these helices have 22 amino 
acids and two have 11 amino acids. The amphipathic α-helices 
are class A helices in which hydrophobic residues occupy one 
face whereas neutral and negatively charged residues occupy 
the other (polar) face with the positively charged lysine and 
arginine residues found between the two faces of the helix.30 
This general structure of apoA-I is highly conserved among 
essentially all mammalian species.30 A major and much 
studied function of HDL and apoA-I is the promotion of 
reverse cholesterol transport involving the transfer of cho-
lesterol from peripheral tissue, including the macrophage 
foam cells of the atherosclerotic lesions, through the plasma 
to the liver whence it is excreted either as free cholesterol or 
bile salt into the feces.31 Two major pathways involving ABC 
transporters have been identified for the efflux of cholesterol 
from lipid-loaded macrophage foam cells to HDL or apoA-I. 
Intact HDL acquires cellular cholesterol via interacting with 
ABCG1, while lipid-poor apoA-I, which can be liberated from 
remodeled HDL, is able to catalyze the removal of cellular 
cholesterol via ABCA1.32,33 The importance of this latter trans-
porter is indicated by the phenotype of patients with Tangier 
disease caused by a deficiency of ABCA1.34 These patients 
have virtually no HDL and exhibit highly lipid-enriched 
foam cells in the reticuloendothelial tissues, eg, tonsils.
Although much attention has been devoted to the 
role of HDL and apoA-I in mediating reverse cholesterol 
transport, it is now becoming more widely recognized that 
HDL has other functions that could potentially influence 
atherosclerosis. These include the inhibition (or attenuation) 
of LDL oxidation, inhibition of type 1 interferon produc-
tion as a consequence of bacterial infection, inhibition of 
chemokine production particularly CCL2 (MCP-1) and 
CCL5 which may be responsible for the recruitment of cells 
into the atherosclerotic plaque, and promotion of the stability 
of endothelial nitric oxide synthase (eNOS) which allows for 
vascular dilation.35–41 Given that diabetes may significantly 
contribute to the risk of atherosclerosis and cardiovascular 
disease, the recent observation that the HDL may promote 
insulin secretion by pancreatic islets is of great interest.42
HDL has additional anti-inflammatory properties. It has 
long been recognized that HDL binds LPS, thus blocking its 
ability to trigger signaling via the CD14/MD2/TLR4   complex.43 
More recently it has been shown that HDL and/or apoA-I   binding 
to ABC transporters on macrophages is anti-inflammatory. 
One indirect mechanism appears to be related to the promo-
tion of lipid efflux thus reducing cell surface rafts leading 
to reduced signaling via TLR4 and perhaps other TLRs.44,45 
Another mechanism appears to be due to apoA-I mediated 
stabilization of ABCA1 resulting in the autophosphorylation 
of JAK2 and activation of STAT3 which promotes an anti-
inflammatory phenotype in the macrophages.46,47 This reduced 
expression of pro-inflammatory cytokines (IL-1, IL-6, and 
TNFα) by macrophages induced by apoA-I is independent of 
the lipid transport activity of ABCA1.47
Although a great deal of attention has been paid to the 
measurement of the level of plasma HDL and to the develop-
ment of therapeutics to increase HDL levels, it is now becom-
ing increasingly recognized that the functional attributes of 
HDL may be as important or perhaps even more important 
than the level in the plasma. One assessment of the function 
of HDL has been based upon an assay developed by Navab 
et al.48 In this assay, human endothelial cells cocultured with 
smooth muscle cells are incubated with plasma LDL. The 
endothelial cell mediated oxidation of the LDL induces the 
production of MCP-1 by the endothelial cells. Upon the 
addition of monocytes to the coculture, the MCP-1 pro-
motes chemotaxis of the monocytes across the monolayer 
of endothelial cells. This assay has been designated the 
“monocyte chemoattractant assay” (MCA) and is dependent 
upon the oxidation of LDL rendering it pro-inflammatory. 
The addition of HDL to the system reduces the recruitment 
of monocytes by lowering the oxidation of LDL, probably 
in major part by extracting oxidized lipids from LDL, and 
thus the production of the chemoattractant.48 HDL needs to 
be constantly present in the culture medium to be effective. 
This assay has been used to assign an anti-inflammatory 
index to different HDL preparations. For example, HDL 
derived from patients with clinically active cardiovascular 
disease exert less anti-inflammatory activity than the HDL 
from control subjects.49 One mechanism by which HDL 
may exert this anti-inflammatory action is attributable 
to its carriage of enzymes capable of cleaving oxidized 
phospholipids–paraoxonase and platelet activating factor 
hydrolase.50 ApoA-I also inhibits the oxidation of LDL, but 
only if it is removed from the coculture system prior to the 
addition of monocytes.51
The apoA-I mimetic peptides
One of the promising potential therapeutics for improving the 
function of HDL is apoA-I mimetic peptides.52 The design Journal of Inflammation Research 2011:4 submit your manuscript | www.dovepress.com
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of the apoA-I mimetic peptides is based upon the general 
structure of the amphipathic α-helical repeats in apoA-I with 
its separation of polar and nonpolar residues on the two faces 
of the helix and distribution of charged residues. The first 
of these peptides was designed by Anantharamaiah et al as 
an 18 amino acid peptide with the general properties of the 
average amphipathic helix of apoA-I without reproducing the 
exact amino acid sequence of any single amphipathic helix 
of the protein.53 The peptide, originally named 18A, had 18 
amino acid residues rather than the 22 amino acids of the 
typical helix because it did not include the residues in the 
junctions between the tandem helices in the protein. Upon 
acetylation of its N-terminus and amidation of its C-terminus, 
its helicity and capacity to associate with lipids is increased. 
This modified peptide is referred to as 2F since it contains two 
phenylalanine residues on the hydrophobic face (Figure 1). 
A tandem helix has been studied, which comprises two 2F 
peptides linked by a proline residue (37pA), the prototypic 
linking residue between many of the repeating helices of 
apoA-I. Both peptides efficiently promote cholesterol efflux 
from cholesterol enriched cells.54 These peptides are also 
capable of solubilizing phospholipid micelles, demonstrating 
their affinity for lipid.55,56
A series of 18 amino acid peptide variants has been fab-
ricated by manipulating the hydrophobic residues of the 2F 
peptide by varying the number of phenylalanine residues on 
the nonpolar face and are named based on the number of phe-
nylalanines in the peptide. The most widely studied of these 
peptides is 4F which has an additional two phenylalanine resi-
dues incorporated into the hydrophobic face in place of leu-
cine residues in 2F at positions 3 and 14 (Figure 1). Thus, 4F 
has phenylalanine residues at four of the eight positions on 
the nonpolar face (at positions 3, 6, 14, and 18). This peptide 
has been shown to efficiently promote cellular cholesterol 
efflux, have high lipid affinity, and is anti-inflammatory in the 
MCA.55,57 Other phenylalanine variants that have been studied 
are: 5F (with phenylalanines at positions 6, 11, 14, 17, and 18), 
6F (with phenylalanines at positions 6, 10, 11, 14, 17, and 18), 
and 7F (with phenylalanines at 7 of the 8   positions). 5F and 
6F are as active as 4F in the MCA whereas the biological 
activity of 2F and 7F is somewhat lower.55
A series of peptides containing three phenylalanines 
located at different positions on the nonpolar face has also 
been studied. The aromatic residues in 3F-1 are close to the 
edges of the nonpolar face near the Lys residues, near the 
center of the nonpolar face in 3F-2, and asymmetrically 
aligned on the nonpolar face in 3F14 (Figure 1). 3F-1 and 
3F-2 are highly active biologically in the MCA in contrast to 
another variant 3F14.58,59 An examination of the position of the 
phenylalanine residues on the nonpolar face does not suggest 
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Figure 1 Helical wheel depiction of the several apoA-i mimetic peptide. Hydrophobic residues are yellow, acidic residue are red, and basic residues are blue. The 
phenylalanine residues are highlighted in red lettering.Journal of Inflammation Research 2011:4 submit your manuscript | www.dovepress.com
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Table 1 In vivo and in vitro properties of active apoA-I mimetic peptides. Comparison of the anti-inflammatory activity of the 
peptides in the monocyte chemotactic assay and effects on early murine atherosclerosis are compared with their ability to solubilize 
the phospholipid POPC and motion of the single tryptophan residue in the peptides. The symbols represent relative levels of activity 
with +++ the highest and - being no activity
Anti-inflammatory  
activity in vitro
Attenuation of early  
atherosclerosis
Phospholipid  
solubilization
Tryptophan   
motion
3F-1 ++ nd + ++
3F-2 ++ ++ ++ ++
3F14 - + +++ +
4F ++ ++ ++ ++
Abbreviations: nd, no data; POPC, palmitoyl oleoyl phosphatidyl choline.
a precise structure-function activity of these   peptides based 
upon the phenylalanine position. The bioactive   peptides 3F-1 
and 3F-2 have larger hydrophobic face than the inactive 3F14. 
On the other hand, the capacity to solubilize palmitoyl oleoyl 
phosphatidyl choline (POPC) phospholipid micelles does not 
correlate with bioactivity: 3F14 is more effective than either 
3F-1 or 3F-2, indicating that other factors than hydrophobic-
ity and lipid affinity are important for their anti-inflammatory 
properties (Table 1).58,59 Correlated with bioactivity is the 
motion of the tryptophan residues in the peptides.58,59 In 3F14, 
this residue is more spatially restricted than is the case for 
4F, 3F-1 or 3F-2.
The anti-inflammatory properties 
of apoA-I mimetic peptides
One of the properties of the mimetic peptide that initially 
excited interest was their anti-inflammatory activity in the 
monocyte chemotactic assay described above. Like apoA-I, 
the apoA-I mimetic peptides are able to inhibit LDL-mediated 
stimulation of monocyte chemotactic activity. But the peptides 
differ from apoA-I in that while apoA-I has to be removed 
from the culture system prior to the addition of monocytes 
in order to reduce the inflammatory activity of the LDL, 
the peptide can continuously remain in the assay media.51,60 
This difference in apoA-I and mimetic peptide behavior is 
probably attributable to a difference in their interaction with 
oxidized lipids. Van Lenten et al have shown that the mimetic 
peptides that are anti-inflammatory in the MCA and attenuate 
atherosclerosis in animal models (ie, 4F, 3F-1, and 3F-2) have 
a very high affinity for oxidized fatty acids and cholesterol as 
well as oxidized phospholipids.60 This affinity is ∼4–6 orders 
of magnitude higher than that of apoA-I. The binding of 
oxidized lipids to the less biologically active mimetic peptide 
3F14 is significantly lower. This has led to the hypothesis that 
the anti-inflammatory activity of the peptides is related to 
their ability to sequester oxidized lipid. Consistent with this is 
the lower levels of oxidized fatty acids in the plasma of mice 
treated with 4F.61 The anti-inflammatory activity of HDL is 
probably attributable to the retention of oxidized lipids in the 
lipid domain without exhibiting the high chemical affinity for 
these lipids that the peptides do. The peptides are also able 
to reverse the pro-inflammatory activity of the dysfunctional 
HDL obtained from patients with clinical atherosclerotic 
disease.62 This is probably attributable to the extraction of 
oxidized lipids from the HDL.
One of the properties in which the peptides resemble 
HDL and apoA-I is their ability to promote reverse choles-
terol transport. 2F, 4F, and the stereochemical isomer of 2F 
synthesized with D amino acids (D2F) are capable of promot-
ing cholesterol efflux from cholesterol loaded macrophages 
and stabilizing ABCA1.46 In addition to interacting with 
ABCA-1, the peptides probably also interact with membrane 
lipids which may be of importance in promoting efflux. We 
have studied tandem peptides consisting of two monomeric 
4F peptides linked by a proline or with a seven amino acid 
interhelical sequence. They also promote cholesterol efflux as 
effectively as the monomeric 4F.57 The 4F peptide has been 
shown to promote reverse cholesterol transport in vivo using 
an assay involving the injection of [3H]-cholesterol labeled, 
lipid load J774 macrophage cell line into the peritoneal cavity 
of mice.63 Whether tandem peptides are more efficient has 
not yet been determined.
Similar to apoA-I, 2F, 4F, and D2F are capable of activat-
ing the autophosphorylation of JAK2.46 Whether phospho-
rylation of Stat3 upon binding to ABCA1 is a property that 
peptides share with apoA-I is yet to be established. However, 
it has been shown that like apoA-I, 4F reduces lipid rafts in 
macrophages and this is correlated with decreased produc-
tion of pro-inflammatory cytokines and chemokines and cell 
surface expression of TLR4.45 The suggestion is that the reduc-
tion in lipid rafts is due to removal of cholesterol which in turn 
modulates the activity of raft associated signaling proteins.
The mimetic peptides have been studied for only some 
of the other functions of HDL and apoA-I mentioned above. Journal of Inflammation Research 2011:4 submit your manuscript | www.dovepress.com
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One function that the peptides share with apoA-I is the ability 
to stimulate eNOS activity and thus facilitating vasodilation of 
blood vessels.64, 65 We have recently observed that treatment of 
mice with 4F leads to an increment in the level of the natural 
antibody EO6/T15 that recognizes oxidized   phospholipids.66 
Antibodies recognizing oxidized phospholipids and other 
oxidation epitopes may attenuate atherosclerosis.67,68
An asymmetrical tandem peptide has been developed 
by Remaley and colleagues. The N-terminal half of this 
peptide consists of 2F and the C-terminal half consists of a 
modified 2F in which each of the hydrophobic residues on 
the nonpolar face of the helix (positions 3, 6, 10, 14, and 18) 
were substituted with an alanine residue.69 Thus, the lipid 
affinities of two halves of the tandem peptide, designed 5A, 
are not identical. The ability of 5A to promote cholesterol 
efflux is less than that of 37pA at low concentration but is 
more active at high concentrations.
A variety of other peptides based upon the C-terminal 
helices of apoA-I and the structure of other HDL-associated 
proteins, ie, apoE, apoJ, and SAA, have also been studied 
for biological activity in some of the above assays. Some 
of these studies have been summarized in a recent review.70 
It is not clear that these peptides all have the capacity to bind 
cytotoxic lipids. The apoE and SAA peptides almost certainly 
act at least in part by promoting reverse cholesterol transport 
and in this way are anti-inflammatory.
The in vivo anti-inflammatory 
activities of the apoA-I  
mimetic peptides
A great deal of interest was elicited in 2002 when the anti-
atherogenic effect of D4F at very low dose was first noted.71 
The peptide was synthesized from D2F to render it resistant 
to proteolysis by intestinal and bacterial enzymes when 
administered orally. Since then, many studies have been 
undertaken to examine the effect of the 4F peptide and 
other mimetic peptides in experimental atherosclerosis, 
predominantly in murine models (see [70] for a summary 
of the studies). Peptides have been administered orally, 
intravenously, and subcutaneously. When the latter two 
routes are employed, 4F containing L-amino acids is active. 
In general, these peptides are most effective at reducing early 
murine lesions, however, there is one report of the 4F peptide 
attenuating the development of more mature lesions when 
peptide treatment was coupled with statin treatment.72 The 
effect of larger doses of peptide as a monotherapy on more 
developed lesions has recently been reported.73 In addition 
to the influence on atherosclerotic lesions, these studies are 
often associated with a reduction in plasma lipid peroxides.63 
In general, peptides with   anti-inflammatory properties are 
also more effective at attenuating atherosclerosis (Table 1). 
While the theory that the peptides attenuate atherosclerosis 
mainly by binding pathogenic oxidized lipids is certainly 
attractive, whether this mechanism is the primary contributor 
to peptide efficacy in vivo has not yet been categorically 
established.
The binding of oxidized lipids at high affinity by the 
active peptides suggested they may be useful agents for the 
treatment of other inflammatory diseases in which oxidized 
lipids are thought to be contributing participants. Thus 
the peptides have been shown to exert anti-inflammatory 
  activity in a variety of inflammatory disorders including viral 
infection, common asthma, renal inflammation, diabetes, 
scleroderma, and sickle cell disease,74,75 and more recently in 
murine models of chronic arthritis, endotoxemia, and lupus 
erythematosis.76–78 Interestingly, in the case of lupus related 
accelerated atherosclerosis, the 4F peptide in combination 
with statin did not reduce lesion size but the composition of 
the lesions was altered with a reduction in macrophage content 
and an increase in smooth muscle cell content. This is compat-
ible with reduced inflammation. Most of the atherosclerosis 
and inflammatory disease studies have been performed with 
the apoE-deficient mouse model in which the oxidative stress 
is higher than in other models.
Human subjects with clinical 
atherosclerotic disease biopsies
The anti-atherosclerotic action of the mimetic peptides in 
preclinical studies has made them very attractive potential 
agents for clinical therapy, especially in view of their apparent 
synergy with statins in mouse models. Two human studies 
have so far been performed. The first was a safety study in 
which a single oral dose of the peptide D4F was given in 
the range 4–8 mg/kg.79 This level of peptide was able to 
substantially improve the inflammatory index in the HDL of 
patients with clinical cardiovascular disease without any toxic 
effects observed. On the other hand, a more recent study by 
Watson et al in which approximately 1/10 of the above dose 
of peptide was given daily intravenously over 7 days or sub-
cutaneously for 28 days was without effect on the biomarkers 
of HDL function.80 This was the outcome despite the fact 
that the maximum plasma concentration of peptide was sub-
stantially higher than was achieved with a single oral dose 
study reported by Bloeden et al.79 In an attempt to under-
stand the differences in the outcome   measures of peptide 
administration in these two human studies, Navab et al have Journal of Inflammation Research 2011:4 submit your manuscript | www.dovepress.com
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recently reported an extensive comparison of the effects of 
various dose of peptides given either orally or subcutaneously 
to apoE-deficient mice on inflammatory markers including 
the HDL inflammatory index and atheroslerosis.73 They found 
that the dose of peptide, irrespective of the method of admin-
istration, was the primary determinant of peptide efficacy, 
not the level of peptide in the plasma or liver. Clearly, much 
more work is needed to establish optimal dosing, route of 
administration, and cotherapies for the treatment of human 
atherosclerotic heart disease and other chronic inflammatory 
disorders using these agents.
Conclusion and perspectives
There is much evidence to suggest powerful anti-atherogenic, 
anti-inflammatory properties of HDL. But therapies tar-
geted at elevating a functionally effective HDL are not far 
advanced. Given the heterogeneity of HDL, this will not 
be easily accomplished. HDL promotes reverse cholesterol 
transport and is anti-inflammatory, two potentially correlated 
functions. The apoA-I mimetic peptide is a much simpler 
reagent for therapeutic purposes than HDL or apoA-I. It too 
may promote reverse cholesterol transport (not yet well 
studied in vivo) and be markedly anti-inflammatory, perhaps 
mainly by binding oxidized fatty acids and phospholipids 
and/or interaction with ABCA1. But there is a need for much 
more basic pharmacology and pharmacodynamic studies in 
animals and humans.
•	 For effective therapy, new modes of peptide delivery 
need to be explored using such devices as subcutaneously 
implanted pumps for constant and regular delivery of 
peptide to the plasma and active tissues.
•	 More precise experiments on the in vivo mechanisms of 
action of the mimetic peptides are needed to ascertain 
what requirements are associated with effective in vivo 
therapy.
•	 Given the observation that peptide therapy in animal 
models may increase the level of antibodies to oxidized 
phospholipid, one wonders whether these peptides 
might be employed as a means of antigen presentation 
of oxidized phospholipid to generate antibodies for the 
removal of oxidized phospholipids. This needs to be more 
intensively explored.
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